Personalized treatment of sezary syndrome by targeting a novel ctla4:Cd28 fusion

Aleksandar Sekulic, Winnie S. Liang, Waibhav Tembe, Tyler Izatt, Semyon Kruglyak, Jeffrey A. Kiefer, Lori Cuyugan, Victoria Zismann, Christophe Legendre, Mark R. Pittelkow, John J. Gohmann, Fernando R. De Castro, Jeffrey Trent, John Carpten, David W. Craig, Timothy K. McDaniel

Research output: Contribution to journalArticlepeer-review

56 Scopus citations


Matching molecularly targeted therapies with cancer subtype-specific gene mutations is revolutionizing oncology care. However, for rare cancers this approach is problematic due to the often poor understanding of the disease’s natural history and phenotypic heterogeneity, making treatment of these cancers a particularly unmet medical need in clinical oncology. Advanced Sezary syndrome (SS), an aggressive, exceedingly rare variant of cutaneous T-cell lymphoma (CTCL) is a prototypical example of a rare cancer. Through whole genome and RNA sequencing (RNA-seq) of a SS patient’s tumor we discovered a highly expressed gene fusion between CTLA4 (cytotoxic T lymphocyte antigen 4) and CD28 (cluster of differentiation 28), predicting a novel stimulatory molecule on the surface of tumor T cells. Treatment with the CTLA4 inhibitor ipi-limumab resulted in a rapid clinical response. Our findings suggest a novel driver mechanism for SS, and cancer in general, and exemplify an emerging model of cancer treatment using exploratory genomic analysis to identify a personally targeted treatment option when conventional therapies are exhausted.

Original languageEnglish (US)
Pages (from-to)130-136
Number of pages7
JournalMolecular Genetics and Genomic Medicine
Issue number2
StatePublished - Mar 2015


  • CD28
  • CTLA4
  • Sezary syndrome

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Genetics(clinical)


Dive into the research topics of 'Personalized treatment of sezary syndrome by targeting a novel ctla4:Cd28 fusion'. Together they form a unique fingerprint.

Cite this